FibroBiologics Faces Second Nasdaq Delisting Threat for Market Value Deficiency
Summary
FibroBiologics, Inc. received formal notice of non-compliance with Nasdaq's market value of listed securities rule, adding a second basis for delisting alongside its existing bid price deficiency.
Key Events
-
Formal Delisting Notice for MVLS
On February 3, 2026, FibroBiologics received formal notice from Nasdaq regarding its continued non-compliance with the $35 million Market Value of Listed Securities (MVLS) rule, which serves as an additional basis for delisting.
-
Compounding Delisting Threats
This MVLS deficiency is in addition to the previously reported non-compliance with Nasdaq's minimum bid price rule, creating two distinct grounds for potential delisting.
-
Awaiting Nasdaq Panel Decision
The company has presented its plan to regain compliance for both the bid price and MVLS rules to the Nasdaq Hearings Panel and is awaiting a formal decision regarding its request for continued listing.
-
Reverse Stock Split Proposed
To address the bid price deficiency, the company filed proxy materials on December 29, 2025, seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30 shares.
Analysis
FibroBiologics, Inc. has received formal notification from Nasdaq regarding its continued non-compliance with the minimum market value of listed securities (MVLS) rule. This deficiency serves as an additional basis for delisting, compounding the previously reported bid price deficiency. The company has presented its plan to regain compliance for both issues to the Nasdaq Hearings Panel, but there is no assurance of an extension or successful resolution. The ongoing delisting threat creates significant uncertainty for investors, as a delisting could severely impact liquidity and investor confidence. The proposed reverse stock split, while a step towards addressing the bid price rule, does not guarantee compliance with the MVLS rule or a favorable decision from Nasdaq.
At the time of this filing, FBLG was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.7M. The 52-week trading range was $0.22 to $2.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.